Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is one of the most severe rare inherited skin disorders affecting children and adults. Current medical care protocols for RDEB patients are limited to palliative procedures to treat blistering and erosive lesions, wounds, and severe local and systemic complications such as fusion and contracture of the digits, skin cancer, esophageal stricture, severe anemia, infections, malnutrition and growth retardation. However, current medical treatments still cannot prevent the recurrence of the lesions arising from defective expression of type VII collagen (COL7A1), the main constituent of anchoring fibrils which form essential structures for dermal-epidermal adherence.
The purpose of this study is to investigate the capacity of keratinocytes and fibroblasts to repair skin wounds in patients suffering from Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Full description
In the perspective of future therapeutic interventions, which could involve protein, cellular and/or gene therapy, it is essential to investigate RDEB patients with regards to their immune tolerance to type VII collagen and their capacity of their cells for tissue reconstruction.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Severity of disease and presence of ill-prognostic features:
Underlying conditions, diseases or active infections likely to increase the risk of complications or to interfere with the biological investigations:
Not affiliated to the national social security/health service beneficiary and families with beneficiary children.
30 participants in 1 patient group
Loading...
Central trial contact
Alain Hovnanian, Prof
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal